Streetbeat News

Price Targets

CHD

Barclays analyst Lauren Lieberman maintains an Underweight rating on Church & Dwight Co (NYSE:CHD) and lowers the price target from $83 to $78.

Portfolio Pulse from Benzinga Newsdesk

July 20, 2023 | 11:03 am

BF

Barclays analyst Lauren Lieberman maintains an Equal-Weight rating on Brown Forman Inc Class B Common Stock (NYSE:BF) and raises the price target from $67 to $70.

Portfolio Pulse from Benzinga Newsdesk

July 20, 2023 | 11:01 am

APLS

Wells Fargo analyst Derek Archila has maintained an Equal-Weight rating on Apellis Pharmaceuticals (NASDAQ:APLS) but lowered the price target from $76 to $53.

Portfolio Pulse from Benzinga Newsdesk

July 20, 2023 | 10:58 am

ATI

Northcoast Research analyst Chris Olin has initiated coverage on ATI (NYSE:ATI) with a Buy rating and announced a price target of $54.

Portfolio Pulse from richadhand@benzinga.com

July 20, 2023 | 10:58 am

NOTV

Wells Fargo analyst Timothy Daley has initiated coverage on Inotiv (NASDAQ:NOTV) with an Overweight rating and a price target of $9.

Portfolio Pulse from richadhand@benzinga.com

July 20, 2023 | 10:57 am

ORLY

Wells Fargo analyst Zachary Fadem has maintained an Overweight rating on O'Reilly Automotive (NASDAQ:ORLY) and raised the price target from $985 to $1075.

Portfolio Pulse from Benzinga Newsdesk

July 20, 2023 | 10:56 am

IAS

Truist Securities analyst Youssef Squali has initiated coverage on Integral Ad Science (NASDAQ:IAS) with a Buy rating and a price target of $25.

Portfolio Pulse from richadhand@benzinga.com

July 20, 2023 | 10:56 am

MSFT

Citigroup analyst Tyler Radke maintains a Buy rating on Microsoft (NASDAQ:MSFT) and raises the price target from $340 to $425.

Portfolio Pulse from Benzinga Newsdesk

July 20, 2023 | 10:54 am

RGEN

Wells Fargo analyst Timothy Daley has initiated coverage on Repligen (NASDAQ:RGEN) with an Overweight rating and a price target of $185.

Portfolio Pulse from richadhand@benzinga.com

July 20, 2023 | 10:53 am

ABOS

B of A Securities analyst Geoff Meacham has reinstated Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy rating and announced a $14 price target.

Portfolio Pulse from richadhand@benzinga.com

July 20, 2023 | 10:52 am